{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:52Z","timestamp":1776439852465,"version":"3.51.2"},"reference-count":32,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Palliative sedation therapy (PST) is used to treat refractory symptoms at the end of life. Phenobarbital is infrequently used as a third-line agent following unsuccessful symptom control with first-line and second-line agents. However, there is wide clinical and guideline variance in the use of phenobarbital, reflecting a gap in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to summarise the current evidence and guidelines surrounding practices of phenobarbital use in PST and discuss areas for future investigations, specifically regarding route of administration, time to death, dosing and concurrent use of first-line and second-line PST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies and guidelines on the use of phenobarbital in PST were retrieved from PubMed and Google and the reference list of identified papers through to August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Limited case studies and retrospective audits have been conducted into the use of phenobarbital in PST. These studies and existing guidelines reflect a degree of variance specifically regarding recommendations about route of administration, dosing and use of first-line and second-line PST. Efficacy is not well reported. However, phenobarbital use appears to be safe and does not appear to impact time to survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Phenobarbital appears to have a safe and potentially efficacious role as a third-line agent in PST. Great variance exists with regards to optimal dosing and the concurrent use of first- and second-line PST agents. High-quality research and multicentre reviews are required to enhance the understanding of optimal phenobarbital use and encourage evidence-based practice in palliative medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2024-005316","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:15:13Z","timestamp":1759472113000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phenobarbital for palliative sedation therapy: narrative review"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1780-0026","authenticated-orcid":false,"given":"Grace","family":"Freeman-Spratt","sequence":"first","affiliation":[{"name":"Palliative Care, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Tan","sequence":"additional","affiliation":[{"name":"Palliative Care, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Kasiri","sequence":"additional","affiliation":[{"name":"Palliative Care, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2026041707351388000_16.1.47.1","unstructured":"Safer Care Victoria . Palliative sedation therapy: statewide guidance for victoria. Safer Care Victoria; 2020."},{"key":"2026041707351388000_16.1.47.2","unstructured":"Cherny N , Smith TJ , Givens J . Palliative sedation. UpToDate; 2024."},{"key":"2026041707351388000_16.1.47.3","unstructured":"Canberra Health Services, Palliative Care Sedation Therapy. 2021."},{"key":"2026041707351388000_16.1.47.4","unstructured":"NSW Health . Subcutaneous phenobarbital for refractory terminal agitation and uncontrolled seizures (including status epilepticus) in the imminently dying patient. NSW Health; 2023."},{"key":"2026041707351388000_16.1.47.5","doi-asserted-by":"crossref","first-page":"iii143","DOI":"10.1093\/annonc\/mdu238","article-title":"ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation","volume":"25 Suppl 3","author":"Cherny","year":"2014","journal-title":"Ann Oncol"},{"key":"2026041707351388000_16.1.47.6","unstructured":"BC Centre for Palliative Care . BC interprofessional palliative symptom management guidelines. New Westminster, 2024."},{"key":"2026041707351388000_16.1.47.7","unstructured":"Faster Health . Refractory symptoms and palliative sedation therapy guideline. Fraser Health; 2011."},{"key":"2026041707351388000_16.1.47.8","unstructured":"Wilcock A , Howard P , Charlesworth S . Palliative care formulary. 8th edn. Royal Pharmaceutical Society, 2022."},{"key":"2026041707351388000_16.1.47.9","unstructured":"Schachter SC , Garcia PA , Dashe JF . Antiseizure medications: mechanism of action, pharmacology, and adverse effects. UpToDate; 2024. Available: https:\/\/www.uptodate.com"},{"key":"2026041707351388000_16.1.47.10","unstructured":"MIMs Medicines Information . Phenobarbitone injection (aspen pharmacare). MIMs; 2024."},{"key":"2026041707351388000_16.1.47.11","unstructured":"Olson k , Smollin c , Anderson I , et al . Poisoning & drug overdose. 8th edn.2022. Available: https:\/\/accessmedicine.mhmedical.com\/book.aspx?bookid=3195"},{"key":"2026041707351388000_16.1.47.12","unstructured":"Drugbank . Phenobarbital. Drugbank. Available: https:\/\/go.drugbank.com\/drugs\/DB01174 [Accessed Oct 2024]."},{"key":"2026041707351388000_16.1.47.13","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2023-004593"},{"key":"2026041707351388000_16.1.47.14","doi-asserted-by":"publisher","DOI":"10.1177\/1049909114555157"},{"key":"2026041707351388000_16.1.47.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-003263"},{"key":"2026041707351388000_16.1.47.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00006-8"},{"key":"2026041707351388000_16.1.47.17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpainsymman.2019.04.019","article-title":"Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study","volume":"58","author":"Won","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2026041707351388000_16.1.47.18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/15360288.2021.1931631","article-title":"A Case Report of Phenobarbital for Proportionate Sedation to Control Refractory Symptoms at the End of Life in an Opioid Tolerant Patient","volume":"35","author":"Jones","year":"2021","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026041707351388000_16.1.47.19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1049909119839695","article-title":"Home Palliative Sedation Using Phenobarbital Suppositories: Time to Death, Patient Characteristics, and Administration Protocol","volume":"36","author":"Setla","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"2026041707351388000_16.1.47.20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jpainsymman.2015.12.339","article-title":"Pharmacokinetics of Phenobarbital in Microenema Via Macy Catheter Versus Suppository","volume":"51","author":"Lam","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2026041707351388000_16.1.47.21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/15360288.2022.2113596","article-title":"Use of Phenobarbitone for Palliative Sedation in Dyspneic Crises Due to COVID-19 Pneumonia \u2013 A Case Series","volume":"36","author":"Sim","year":"2022","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026041707351388000_16.1.47.22","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309351383"},{"key":"2026041707351388000_16.1.47.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.03.016"},{"key":"2026041707351388000_16.1.47.24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.3.341"},{"key":"2026041707351388000_16.1.47.25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/10499091231164135","article-title":"Extreme Symptom Burden for Patients With COVID-19 at the End of Life; Extrapolation of Knowledge Gained to Achieve Sustained Comfort and Dignity for all Patients in Their Last Days of Life1","volume":"41","author":"Waldron","year":"2024","journal-title":"Am J Hosp Palliat Care"},{"key":"2026041707351388000_16.1.47.26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/02692163241257580","article-title":"Bispectral Index monitoring of palliative sedation for home withdrawal of tracheostomy ventilation: A case report","volume":"38","author":"Barclay","year":"2024","journal-title":"Palliat Med"},{"key":"2026041707351388000_16.1.47.27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/17843286.2017.1331783","article-title":"Suboptimal palliative sedation in primary care: an exploration","volume":"73","author":"Pype","year":"2018","journal-title":"Acta Clin Belg"},{"key":"2026041707351388000_16.1.47.28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpainsymman.2018.03.008","article-title":"Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study","volume":"56","author":"Caraceni","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"2026041707351388000_16.1.47.29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(15)00401-5","article-title":"Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study","volume":"17","author":"Maeda","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026041707351388000_16.1.47.30","doi-asserted-by":"publisher","DOI":"10.1177\/026921639701100208"},{"key":"2026041707351388000_16.1.47.31","doi-asserted-by":"publisher","DOI":"10.1177\/0018578717720310"},{"key":"2026041707351388000_16.1.47.32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ajem.2022.02.020","article-title":"Phenobarbital and\/or benzodiazepines for recurrent alcohol withdrawal: A self-controlled, retrospective cohort study","volume":"54","author":"Staidle","year":"2022","journal-title":"Am J Emerg Med"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2024-005316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:36:19Z","timestamp":1776436579000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2024-005316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/spcare-2024-005316"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2024-005316","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}